{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:18:54Z","timestamp":1778073534537,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00702-025-02939-7","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T07:49:25Z","timestamp":1747381765000},"page":"619-633","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protective effect of formononetin in chronic unpredictable stress (CUS) linked to parkinson disease"],"prefix":"10.1007","volume":"133","author":[{"given":"Tanvi Dayanand","family":"Pingale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girdhari Lal","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"2939_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3389\/fneur.2019.00399","volume":"10","author":"ST Auti","year":"2019","unstructured":"Auti ST, Kulkarni YA (2019) Neuroprotective effect of cardamom oil against aluminum induced neurotoxicity in rats. Front Neurol 10:399. https:\/\/doi.org\/10.3389\/fneur.2019.00399","journal-title":"Front Neurol"},{"key":"2939_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.pbb.2012.12.020","volume":"104","author":"PP Baptista","year":"2013","unstructured":"Baptista PP, de Senna PN, Paim MF, Saur L, Blank M, do Nascimento P, Ilha J, Vianna MR, Mestriner RG, Achaval M, Xavier LL (2013) Physical exercise down-regulated locomotor side effects induced by haloperidol treatment in Wistar rats. Pharmacol Biochem Behav 104:113\u2013118. https:\/\/doi.org\/10.1016\/j.pbb.2012.12.020","journal-title":"Pharmacol Biochem Behav"},{"key":"2939_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3389\/fnbeh.2014.00290","volume":"8","author":"A Bonito-Oliva","year":"2014","unstructured":"Bonito-Oliva A, Masini D, Fisone G (2014) A mouse model of non-motor symptoms in Parkinson\u2019s disease: focus on Pharmacological interventions targeting affective dysfunctions. Front Behav Neurosci 8:290. https:\/\/doi.org\/10.3389\/fnbeh.2014.00290","journal-title":"Front Behav Neurosci"},{"issue":"2","key":"2939_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.pbb.2012.05.003","volume":"102","author":"B Bricker","year":"2012","unstructured":"Bricker B, Jackson T, Boateng B, Zhu XY, Ablordeppey SY (2012) Evaluation of the behavioral and Pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats. Pharmacol Biochem Behav 102(2):294\u2013301. https:\/\/doi.org\/10.1016\/j.pbb.2012.05.003","journal-title":"Pharmacol Biochem Behav"},{"key":"2939_CR5","doi-asserted-by":"publisher","first-page":"e3638a","DOI":"10.3791\/3638","volume":"59","author":"A Can","year":"2012","unstructured":"Can A, Dao DT, Arad M, Terrillion CE, Piantadosi SC, Gould TD (2012a) The mouse forced swim test. J Visualized Experiments: JoVE 59:e3638a. https:\/\/doi.org\/10.3791\/3638","journal-title":"J Visualized Experiments: JoVE"},{"key":"2939_CR6","doi-asserted-by":"publisher","unstructured":"Can A, Dao DT, Terrillion CE, Piantadosi SC, Bhat, Gould S (2012b) TD The tail suspension test. Journal of visualized experiments: JoVE (59),e3769. b. https:\/\/doi.org\/10.3791\/3769","DOI":"10.3791\/3769"},{"issue":"2","key":"2939_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s13311-012-0104-2","volume":"9","author":"MF Chesselet","year":"2012","unstructured":"Chesselet MF, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR (2012) A progressive mouse model of Parkinson\u2019s disease: the Thy1-aSyn (Line 61) mice. Neurotherapeutics: J Am Soc Experimental Neurother 9(2):297\u2013314. https:\/\/doi.org\/10.1007\/s13311-012-0104-2","journal-title":"Neurotherapeutics: J Am Soc Experimental Neurother"},{"issue":"1","key":"2939_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13041-018-0356-9","volume":"11","author":"E Dall\u00e9","year":"2018","unstructured":"Dall\u00e9 E, Mabandla MV (2018) Early life stress, depression and Parkinson\u2019s disease: A new approach. Mol Brain 11(1):18. https:\/\/doi.org\/10.1186\/s13041-018-0356-9","journal-title":"Mol Brain"},{"issue":"9","key":"2939_CR9","first-page":"590","volume":"40","author":"G DeMaagd","year":"2015","unstructured":"DeMaagd G, Philip A (2015) Part 2: introduction to the pharmacotherapy of Parkinson\u2019s disease, with a focus on the use of dopaminergic agents. P T: peer-reviewed J Formulary Manage 40(9):590\u2013600","journal-title":"P T: peer-reviewed J Formulary Manage"},{"key":"2939_CR10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3389\/fnins.2018.00612","volume":"12","author":"FN Emamzadeh","year":"2018","unstructured":"Emamzadeh FN, Surguchov A (2018) Parkinson\u2019s disease: biomarkers, treatment, and risk factors. Front Neurosci 12:612. https:\/\/doi.org\/10.3389\/fnins.2018.00612","journal-title":"Front Neurosci"},{"key":"2939_CR11","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.bbr.2019.02.025","volume":"17","author":"J Fernandes","year":"2019","unstructured":"Fernandes J, Gupta GL (2019) N-acetylcysteine attenuates neuroinflammation associated depressive behavior induced by chronic unpredictable mild stress in rat. Behav Brain Res 17:364:356\u2013365. https:\/\/doi.org\/10.1016\/j.bbr.2019.02.025","journal-title":"Behav Brain Res"},{"issue":"12","key":"2939_CR12","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.3390\/life13122261","volume":"3","author":"DN Florescu","year":"2023","unstructured":"Florescu DN, Boldeanu MV, \u0218erban RE et al (2023) Correlation of the Pro-Inflammatory cytokines IL-1\u03b2, IL-6, and TNF-\u03b1, inflammatory markers, and tumor markers with the diagnosis and prognosis of colorectal Cancer. Life (Basel) 3(12):2261. https:\/\/doi.org\/10.3390\/life13122261","journal-title":"Life (Basel)"},{"key":"2939_CR13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.neurobiolaging.2018.01.020","volume":"65","author":"G Giraldo","year":"2018","unstructured":"Giraldo G, Brooks M, Giasson BI, Janus C (2018) Locomotor differences in mice expressing wild-type human \u03b1-synuclein. Neurobiol Aging 65:140\u2013148. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.01.020","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2939_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.expneurol.2011.09.035","volume":"233","author":"AM Hemmerle","year":"2012","unstructured":"Hemmerle AM, Herman JP, Seroogy KB (2012) Stress, depression and Parkinson\u2019s disease. Exp Neurol 233(1):79\u201386. https:\/\/doi.org\/10.1016\/j.expneurol.2011.09.035","journal-title":"Exp Neurol"},{"issue":"1","key":"2939_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11481-011-9269-4","volume":"7","author":"JA Hutter-Saunders","year":"2012","unstructured":"Hutter-Saunders JA, Gendelman HE, Mosley RL (2012) Murine motor and behavior functional evaluations for acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication. J Neuroimmune Pharmacology: Official J Soc NeuroImmune Pharmacol 7(1):279\u2013288. https:\/\/doi.org\/10.1007\/s11481-011-9269-4","journal-title":"J Neuroimmune Pharmacology: Official J Soc NeuroImmune Pharmacol"},{"key":"2939_CR18","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.pbb.2014.06.005","volume":"124","author":"PP Kale","year":"2014","unstructured":"Kale PP, Addepalli V (2014) Augmentation of antidepressant effects of Duloxetine and bupropion by caffeine in mice. Pharmacol Biochem Behav 124:238\u2013244. https:\/\/doi.org\/10.1016\/j.pbb.2014.06.005","journal-title":"Pharmacol Biochem Behav"},{"key":"2939_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1744-9081-8-21","author":"RA Khan","year":"2012","unstructured":"Khan RA, Khan MR, Sahreen S (2012) Brain antioxidant markers, cognitive performance and acetylcholinesterase activity of rats: efficiency of Sonchus asper. Behav Brain Functions: BBF. https:\/\/doi.org\/10.1186\/1744-9081-8-21. 8,21","journal-title":"Behav Brain Functions: BBF"},{"key":"2939_CR16","doi-asserted-by":"publisher","unstructured":"Laura FM, Olivatto, Debora MG, Cunha LB, Silva AC, Lima M, Becegato VS, Bioni RH, Silva (2024) Unpredictable mild stress accelerates the emergence of motor deficits in a rat model of progressive parkinsonism. Advanced Neurology 3(4), 4037. https:\/\/doi.org\/10.36922\/an.4037","DOI":"10.36922\/an.4037"},{"issue":"1\u20132","key":"2939_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jns.2014.06.033","volume":"344","author":"K Liang","year":"2014","unstructured":"Liang K, Ye Y, Wang Y, Zhang J, Li C (2014) Formononetin mediates neuroprotection against cerebral ischemia\/reperfusion in rats via downregulation of the Bax\/Bcl-2 ratio and upregulation PI3K\/Akt signaling pathway. J Neurol Sci 344(1\u20132):100\u2013104. https:\/\/doi.org\/10.1016\/j.jns.2014.06.033","journal-title":"J Neurol Sci"},{"key":"2939_CR21","doi-asserted-by":"publisher","unstructured":"Liu MY, Yin CY, Zhu LJ, Zhu XH, Xu C, Luo CX, Chen H, Zhu DY, Zhou QG (2018) Sucrose preference test for measurement of stress-induced anhedonia in mice. Nat Protoc 13(7):1686\u20131698. https:\/\/doi.org\/10.1038\/s41596-018-0011-z. PMID: 29988104","DOI":"10.1038\/s41596-018-0011-z"},{"issue":"8","key":"2939_CR17","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.3390\/ijms23084148","volume":"23","author":"TW Liu","year":"2022","unstructured":"Liu TW, Chen CM, Chang KH (2022) Biomarker of neuroinflammation in Parkinson\u2019s disease. Int J Mol Sci 23(8):4148. https:\/\/doi.org\/10.3390\/ijms23084148","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2939_CR22","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1002\/ptr.8192","volume":"38","author":"D Madhubala","year":"2024","unstructured":"Madhubala D, Patra A, Khan MR, Mukherjee AK (2024) Phytomedicine for neurodegenerative diseases: the road ahead. Phytother Res 38(6):2993\u20133019. https:\/\/doi.org\/10.1002\/ptr.8192","journal-title":"Phytother Res"},{"issue":"1","key":"2939_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3233\/JPD-189004","volume":"9","author":"K McFarthing","year":"2019","unstructured":"McFarthing K, Simuni T (2019) Clinical trial highlights: targetting Alpha-Synuclein. J Parkinsons Dis 9(1):5\u201316. https:\/\/doi.org\/10.3233\/JPD-189004","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"2939_CR23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3233\/JPD-219006","volume":"11","author":"K McFarthing","year":"2021","unstructured":"McFarthing K, Rafaloff G, Baptista MAS, Wyse RK, Stott SRW (2021) Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2021 update. J Parkinsons Dis 11(3):891\u2013903. https:\/\/doi.org\/10.3233\/JPD-219006","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"2939_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40478-024-01797-w","volume":"12","author":"M Nakos Bimpos","year":"2024","unstructured":"Nakos Bimpos M, Karali K, Antoniou C et al (2024) Alpha-synuclein-induced stress sensitivity renders the Parkinson\u2019s disease brain susceptible to neurodegeneration. Acta Neuropathol Commun 12(1):100 Published 2024 Jun 17. https:\/\/doi.org\/10.1186\/s40478-024-01797-w","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"2939_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1460-9568.2009.06806.x","volume":"30","author":"T Nayyar","year":"2009","unstructured":"Nayyar T, Bubser M, Ferguson MC, Neely MD, Shawn Goodwin J, Montine TJ, Deutch AY, Ansah TA (2009) Cortical serotonin and norepinephrine denervation in parkinsonism: Preferential loss of the beaded serotonin innervation. Eur J Neurosci 30(2):207\u2013216. https:\/\/doi.org\/10.1111\/j.1460-9568.2009.06806.x","journal-title":"Eur J Neurosci"},{"issue":"3","key":"2939_CR27","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3390\/ijms21031170","volume":"21","author":"E Palasz","year":"2020","unstructured":"Palasz E, Wysocka A, Gasiorowska A, Chalimoniuk M, Niewiadomski W, Niewiadomska G (2020) BDNF as a promising therapeutic agent in Parkinson\u2019s disease. Int J Mol Sci 21(3):1170. https:\/\/doi.org\/10.3390\/ijms21031170","journal-title":"Int J Mol Sci"},{"key":"2939_CR28","doi-asserted-by":"publisher","first-page":"628845","DOI":"10.3389\/fnut.2021.628845","volume":"8","author":"NC Palavra","year":"2021","unstructured":"Palavra NC, Lubomski M, Flood VM, Davis RL, Sue CM (2021) Increased added sugar consumption is common in Parkinson\u2019s disease. Front Nutr 8:628845. https:\/\/doi.org\/10.3389\/fnut.2021.628845","journal-title":"Front Nutr"},{"key":"2939_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3389\/fncir.2017.00110","volume":"11","author":"G Rizzi","year":"2017","unstructured":"Rizzi G, Tan KR (2017) Dopamine and acetylcholine, a circuit point of view in Parkinson\u2019s disease. Front Neural Circuits 11:110. https:\/\/doi.org\/10.3389\/fncir.2017.00110","journal-title":"Front Neural Circuits"},{"key":"2939_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-022-02799-2","author":"WZC See","year":"2022","unstructured":"See WZC, Naidu R, Tang KS (2022) Cellular and molecular events leading to Paraquat-Induced apoptosis: mechanistic insights into Parkinson\u2019s disease pathophysiology. Mol Neurobiol Doi. https:\/\/doi.org\/10.1007\/s12035-022-02799-2","journal-title":"Mol Neurobiol Doi"},{"issue":"4","key":"2939_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.molmed.2013.02.003","volume":"19","author":"LP van der Heide","year":"2013","unstructured":"van der Heide LP, Smidt MP (2013) The BCL2 code to dopaminergic development and Parkinson\u2019s disease. Trends Mol Med 19(4):211\u2013216. https:\/\/doi.org\/10.1016\/j.molmed.2013.02.003","journal-title":"Trends Mol Med"},{"key":"2939_CR32","doi-asserted-by":"publisher","unstructured":"Wang XS, Guan SY, Liu A, Jiao Yue Li-ning, Hu K, Zhang Liu-kun, Yang L, Lu Z, Tian Ming-gao Zhao & Shui-bing Liu (2019) anxiolytic effects of Formononetin in an inflammatory pain mouse model. Mol Brain 12(1):36. https:\/\/doi.org\/10.1186\/s13041-019-0453-4","DOI":"10.1186\/s13041-019-0453-4"},{"issue":"4","key":"2939_CR33","doi-asserted-by":"publisher","first-page":"137","DOI":"10.22037\/ijpr.2021.115705.15484","volume":"20","author":"M Xia","year":"2021","unstructured":"Xia M, Zhao T, Wang X, Li Y, Li Y, Zheng T, Li J, Feng Y, Wei Y, Sun P (2021) Brain-derived neurotrophic factor and its applications through nanosystem delivery. Iran J Pharm Res 20(4):137\u2013151. https:\/\/doi.org\/10.22037\/ijpr.2021.115705.15484","journal-title":"Iran J Pharm Res"},{"key":"2939_CR34","unstructured":"Xu H, An D, Yin SM, Chen W, Zhao D, Meng X, Yu DQ, Sun YP, Zhao J, Zhang WQ (2015) [The alterations of apoptosis factor Bcl-2\/Bax in the early Parkinson\u2019s disease rats and the protective effect of scorpion venom derived activity peptide] Zhongguo Ying Yong Sheng Li Xue Za Zhi. Chinese (3):225-9"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-02939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-02939-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-02939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:56:56Z","timestamp":1778072216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-02939-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2939"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-02939-7","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We declare that we have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}